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Authors’ reply
Sir—We thank Robless and colleagues
for their comments, and agree that
measurement of carotid stenosis with
non-invasive methods of imaging 
is problematic. In the randomised 
trials of endarterectomy for sympto-
matic carotid stenosis, doppler
ultrasonography was sometimes used to
screen patients, but conventional
arterial angiography was a prerequisite
for randomisation, as was normal
practice at that time. Although there
are good arguments for the continued
use of catheter angiography before
possible endarterectomy,1 routine
clinical practice in many centres is
based solely on non-invasive imaging. 
Non-invasive methods should,
therefore, be properly validated against
conventional angiography. An aim of
our paper was to provide as precise
estimates as possible of the balance 
of risk and benefit of carotid
endarterectomy, according to a single
angiographic method of measurement
of stenosis that was used in the
NASCET trial and is used almost
universally in North America. We
suggested that this method should be
the standard on which future clinical
practice should be based. We agree that
many vascular imaging laboratories
outside North America use ultraso-
nography criteria validated against the
ECST method of measurement. We
also suspect that some laboratories are
not aware of which method their
criteria have been validated against. We
disagree, however, that continued use
of the two different methods of
measurement is the way to avoid
confusion and unnecessary surgery.
The best way forward is for all 
non-invasive methods of imaging to 
be properly validated against a single
standard angiographic method of
measurement. Unfortunately, many 
of the published validations are
inadequate.2
We disagree with Russell and
colleages that validation of
ultrasonography against angiography is
no longer possible within centres. Many
centres still use both methods of
imaging, and studies have reported high
rates of inappropriate surgery when
decisions are based on ultrasonography
alone.3 Health workers need to
understand that any benefit of non-
invasive imaging in terms of avoidance
of the small procedural risk of catheter
angiography will be reversed if only a
small proportion of patients with
recently symptomatic 70–99% stenosis
are wrongly diagnosed as having an
occlusion or a lesser stenosis such that
they do not receive surgery. However,
we agree that more research is needed
into how best to monitor performance
in individual centres. 
We agree with Robless and
colleagues that benefit from
endarterectomy in patients with
50–69% stenosis was relatively small
compared with the considerable benefit
noted in patients with 70–99% stenosis
without near-occlusion, and we
emphasised this fact in our report.
However, the absolute reduction in the
5-year risk of any stroke or death was
still 8% (95% CI 3·1–12·5, p<0·002)
and increased with further follow-up. In
patients with 60–69% stenosis, the
absolute risk reduction at 8 years was
15% (number needed to treat was
seven). These effects compare
favourably with the 5-year absolute risk
reductions in major vascular events
(stroke, myocardial infarction, and
vascular death combined) obtained in
high-profile trials of medical therapies
in vascular disease, such as the LIFE
trial (2%), the HOPE trial (4%), the
PROGRESS trial (6%), and the Heart
Protection Study (5%).
Further work is needed to identify
high-risk subgroups and individuals
with 50–69% stenosis in whom surgery
would be worthwhile,4,5 and also to
ascertain the effect of the timing of
surgery on benefit. However, there is
unequivocal evidence of some overall
benefit (assuming that operative risk
does not exceed that in the trials).
Whether the benefit is clinically
worthwhile is a decision for individual
patients, clinicians, and health-service
funders.
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Spanish name indexing
errors in international
databases
Sir—The issue raised in an earlier
Correspondence letter (Jan 25, p 351)1
regarding errors in indexing Spanish
names was investigated by us in detail in
a study2 that measured variability in
Medline and Science Citation Index.
The main problem is that indexing
algorithms designed for Anglo-Saxon
names are inappropriate for handling
the structure of Spanish names. 
However, Fernández and García do
not give the National Library of
Medicine due credit for their efforts to
adapt their indexing practices to Spanish
names. In the sample we studied, we
noted that Medline correctly indexes
most Spanish names (89·3%). The type
of example given by Fernández and
García (Juan Ramón González being
indexed as Ramon Gonzalez J instead of
Gonzalez JR) would account for only
0·3% of all errors. Medline’s indexing
algorithm works correctly with Spanish
names consisting of three elements;
what it cannot do is distinguish whether
the second name in a sequence of three
elements is a middle name or a first
surname.
By contrast, the Institute for
Scientific Information (ISI) databases
contain more errors. The general rule
followed by the ISI is that the final name
presented is taken as the surname—this
rule applies to all languages. All other
names presented are processed as
initials. Even so, 76% of all Spanish
names are correctly indexed in these
sources. We suspect that about half of
all Spanish authors might take
precautions to adapt their name to
Anglo-Saxon structures for articles they
know will be indexed in Science
Citation Index and other ISI sources,
either by deleting their second surname
or by hyphenating their two surnames. 
What do these indexing practices
show? How can we explain the fact that
about half of all Spanish authors seem
to have lost their second surname? The
answer is clear: bibliographic databases
produced in English-speaking countries
have been mishandling non-Anglo-
Saxon names for years. As a survival
strategy, Spanish-speaking authors—
and perhaps those in other countries—
have been adapting their name to the
English structure. 
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Sir—During the five decades of my
medical career, I have seen gentian violet
used as an anthelmintic (enteric-coated
tablets administered orally for
entrobiasis), a local antibacterial and
antifungal surface agent, a laboratory
stain, a fungal inhibitor in culture media,
and to improve visualisation of surface
sutures,1 not to mention its use as a dye
for labelling and marking.
Restrictions on the use of this
chemical have now been imposed in the
UK and Australia, based on reports of
its mutagenic and carcinogenic effects 
in animals. However, after centuries 
of use, there is not a single report 
linking gentian violet to cancer in 
human beings.1 Furthermore, in the
National Toxicology Program (NTP)
Study2 on New Zealand white rabbits,
no evidence of teratogenicity of gentian
violet was recorded. That this cheap and
effective antiseptic agent still retains 
its place in the US Pharmacopeia is
reassuring.
Ishak Mansi3 has not only restated the
benefits of a largely abandoned, though
useful and inexpensive topical antiseptic,
but also touched on the almost obsessive
apprehensions of every practising
clinician: what if even in doing their best
for a patient, a much-advertised trial
lawyer finds fault with their handling of
the individual? 
From the instant a doctor has first
contact with a patient, to weeks, months,
and years afterwards, he or she has to
live in the shadow of an impending
lawsuit.
This is not the art of medicine one
dreamed of, or was trained for. In such a
scenario, even the patient does not get
treated in the best traditions of
medicine; unnecessary investigations are
ordered, and the most expensive
medicines prescribed even for trivial
ailments. This trend has sent the cost of
medical care skyrocketing and has
forced doctors into early retirement due
to appalling costs of malpractice
insurance.
By all accounts, medical practice is in
need of a renaissance, the signs of which
I do not see on the horizon.
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Pesticide regulations in 
Sri Lanka
Sir—We concur with Saroj Jayasinghe
and Damani de Silva (Jan 18, p 259),1
in their response to our Public health
report,2 that pesticide advertising in
developing countries could be more
extensively regulated. However, all
pesticide advertisements in Sri Lanka
follow a 17-point guideline, which is
based on the Food and Agriculture
Organisation of the United Nation’s
International Code of Conduct on
Distribution and Use of Pesticides.
Moreover, in Sri Lanka compliance
with the guidelines is monitored.
Jayasinghe and de Silva contend that
“administrative inertia” is one of the
main causes of pesticide problems in
Sri Lanka. However, compared with
many other developing countries, the
Pesticide Registrar in Sri Lanka has
been successful in regulating
pesticides.3 For example, the most
prominent poisons in the current
epidemic of fatal self-harm among rural
women in China are parathion and
dichlorvos, which are WHO class I
(highly hazardous) organophosphate
pesticides.4 All WHO class I pesticides
were banned in Sri Lanka during the
early 1990s. The common pesticides
now in use are the less toxic WHO class
II (moderately hazardous) organophos-
phates, such as chlorpyrifos and
dimethoate.
After the banning of WHO class I
pesticides, the class II organochlorine
insecticide, endosulfan, became the
most commonly used pesticide in
suicide attempts in some rural
communities and an important cause
of status epilepticus.5 Endosulfan was
banned in 1998 and deaths from this
pesticide in Anuradhapura hospital
fell progressively from 27 in 1998 
to three in 2001 (D Roberts,
unpublished observation). The total
number of deaths caused by pesticides
fell by the same number—there was
no apparent switching to other
pesticides.
There are other examples of active
pesticide regulation in Sri Lanka.
Jayasinghe and de Silva are wrong
when they suggest that “any toxic
pesticide” is available in Sri Lanka. 
Although we agree that stricter
regulation would be beneficial, 
there is a powerful counterview. 
The turnover of the pesticide 
industry is $29 billion; that of 
just one agrochemical/pharmaceutical
multinational surpasses $5 billion.
Industry resources dwarf those
available to the government for
regulation of pesticides. The size of
Culture and infection
control
Sir—Ishak Mansi (Jan 18, p 268)1
contemplated the treatment of a
patient’s decubitus ulcer with gentian
violet, before thoughts of lawyers and
hospital committees frightened him into
writing a prescription for linezolid.
Until now, we had assumed that our
own profession (infection control)
would be immune to the influence of
such “cultural” factors. This was until
last month, when we learned that
alcohol-based hand rubs might be
banned from public places in the USA
(eg, hospital hallways) because they
could be seen as a fire hazard. This
revelation coincided with the
recognition in the USA of the advantage
of hand disinfection over handwashing.2
Alcohol-based rubs have been used in
Europe for as long as 30 years. At no
point have they been reported to cause a
fire hazard.
How significant can this fire hazard
be? When Kramer and colleagues3
published their findings on the
difference in the in-vitro effectiveness of
alcohol-based hand rubs and gels,
others rightly questioned whether this
small in-vitro difference would translate
to our hospitals, where compliance with
the method is clearly the most important
factor. Banning alcohol-based hand
rubs from hospital use (or even from
parts of the hospital) would be ignoring
the fact that, in terms of infection
control, hand hygiene has the single
most important effect on hospital
morbidity and mortality.
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